Although adjuvant chemotherapy (CTx) has been a strong contributor to the overall effect, only a small proportion of patients individually benefit from the treatments they receive. Medline and the Cochrane Library. In addition, relevant previously published review articles were consulted to be certain that appropriate reports were not overlooked.
Although adjuvant chemotherapy (CTx) has been a strong contributor to the overall effect, only a small proportion of patients individually benefit from the treatments they receive. 2 Commercially available gene expression assays are promoted as a window into intrinsic tumor biology allowing a more accurate determination of prognosis and treatment benefit than traditional clinicopathologic classifiers.
Haddow and Polamaki's framework for the evidence-based evaluation of genomic assays identifies components essential for any new test. 3, 4 Analytic validity represents an assay's ability to accurately and reproducibly measure biomarkers of interest.
Clinical validity requires the assay to provide accurate and reliable information regarding outcomes of relevance. 5 Clinical utility reflects an assay's ability to favorably alter patient outcome.
[Correction added on 7 March 2017, after first online publication: In the first paragraph of the Oncotype DX section, 180 was replaced with 18.] The Tumor Marker Utility Grading System (TMUGS) grades evidence on a progressive scale. 6 The best evidence comes from completely prospective, controlled clinical trials (Level A). A lower level of evidence (LOE) are prospective-retrospective studies (Level B) with a prospective study design of archived tissue from a previous prospective clinical trial. 7 Two concordant Level B trials can achieve Level I evidence. Prospective evaluation of previously collected patient registry data (level C), represents a lower LOE, but provides opportunity to confirm findings from higher LOE studies. Post hoc investigations, using convenience samples, in the absence of defined treatment, data acquisition, or follow-up, are prone to bias and represent the lowest LOE (level D). These should only be used for general confirmation of higher-level data or for hypothesis generation.
TMUGS is summarized in Table 1 .
Currently there are six commercial gene expression assays available worldwide for patients with early stage breast cancer (ESBC). This review identifies the relevant supporting data for these assays graded by TMUGS LOE.
| MATERIALS AND METHODS

| Article sources
A systematic search of the scientific literature was conducted in September 2016 that identified primary published studies describing the clinical validation of one of the six commercially available genomic classifiers for breast cancer (Table 2 .
) Databases searched included
Medline and the Cochrane Library. In addition, relevant previously published review articles were consulted to be certain that appropriate reports were not overlooked.
| Search strategy
A keyword search strategy was implemented for the initial search of databases that included "BCI," "Breast Cancer Index," "HOXB13/ IL17BR," "MGI," "Molecular Grade Index," "IHC4," "Oncotype," "21
gene," "Recurrence Score," "MammaPrint" "70 gene," "BluePrint, "TargetPrint," "PAM 50," "intrinsic subtype," "Endopredict," and "Prosigna."
| Study selection and data extraction
Only English-language publications were selected. Studies analyzed original data relevant to clinical validity or clinical utility and included a formal statistical test of pre-specified outcome endpoints. Epidemiological, exploratory, and purely descriptive studies were excluded. As this review focuses on decision-making in the immediate postoperative adjuvant setting, we have not included an evaluation of gene expression assays in the setting of neoadjuvant or extended adjuvant therapy, even when the LOE was high (e.g., Sgroi et al. 8 ). Excluded also were publications not relating to female invasive breast cancer and studies without peerreviewed publication. Final reports published in E-format were eligible. All eligible articles were fully reviewed by the investigators to determine that the study met the prespecified requirements.
The PRISMA flow diagram for this review is presented in Fig. S1 .
| Study analysis
A total of 34 articles were identified for inclusion in this analysis (Table   S1 ). Data from each article selected was captured in a structured abstraction form. The framework from Simon and colleagues was used to evaluate the LOE of the identified studies. 7 Each element of the 
| Breast cancer index
The Breast Cancer Index (BCI) is a multi-gene quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assay with two components, the HOXB13:IL17BR ratio (H/I) and the Molecular Grade Index (MGI). 9 The H/I ratio was derived by evaluating differential gene expression in 60 tamoxifen-treated (TAM+) estrogen receptorpositive (ER+) postmenopausal ESBC patients. 10 The MGI component of BCI was developed by identifying genes differentially expressed between tumors of low and high grade, focusing on those involved in invasive growth. 9, 11 The H/I ratio and the MGI have been the subject of independent prognostic validation studies. As the individual components are not used separately in commercial assays, their supportive studies are not reviewed here. 9, 12, 13 The BCI assay was trained in 314 samples of postmenopausal CI 1.16-4.19; P = 0.014), or St. Gallen 2011 guidelines (HR 2.78 95% CI 1.50-5.14; P < 0.001). 20 EPclin reassigned 58 (61%) of patients guideline-classified as high-risk to EPclin low-risk. However, the clinical guidelines of the era classified over 80% of the patients as high-risk to begin with. Ultimately, the authors suggested that the preponderance of truly low-risk patients in this cohort limited the statistical power of the study, proposing that the analyses for the remaining high-clinical-risk subgroup be regarded as exploratory.
The authors suggested CTx for the high-risk group, but there was no evidence presented to support EPclin as a predictor of CTx benefit.
Martin studied the prognostic properties of EP and EPclin in an independent cohort of 555 patients with ER+ LN+ disease from the 1246 patient prospective GEICAM 9906 study treated with CTx and ETx. 21 Both EP and EPclin-defined risk groups were significantly associated with distant metastasis free survival (DMFS) (log rank The prognostic capability of EP and EPClin were compared to Oncotype DX using 928 RNA samples from the ATAC study, previously prepared by Genomic Health. 22 In a multivariate analysis, the EP, EPClin, and the Oncotype DX assay were all prognostic for 10-year DR. EP provided more prognostic information than the Oncotype DX Recurrence Score (RS) in the 5-10 year interval, but the assays were equally prognostic from 0 to 5 years. Clinical factors in the EPClin score resulted in prognostic information that exceeded both the RS and EP. However, clinical factors were not generated by the assay and were not similarly incorporated into the RS data, making any direct comparison of EPclin and Oncotype DX problematic.
The genomic component of these assays sorts patients into low and high-risk groups of different sizes: EP classified more patients as highrisk (58.4%) compared to the Oncotype DX assay, which classified 38.3% with a "non-low" RS (RS ≥ 18). The hazard ratio for 10-year DRS between the low-risk and non-low risk patients was 2.98 (95%CI 1.94-4.58, P < 0.001) for EP compared to HR = 2.73 (95%CI 1.91-3.89, P < 0.001) for Oncotype DX). Although the HR's are similar and the confidence intervals overlap, a larger proportion of EP patients would be considered high-risk and might receive recommendation for CTx.
Martin, et al, more recently evaluated patients from the same GEICAM 9906 study and compared prognostic features of EP and
EPclin with a non-commercial research version of PAM50. 23 However, the comparison does not represent a real-world evaluation of the Prosigna assay, providing little value for practical decision-making.
| IHC4
IHC4 is an integrated immunohistochemistry (IHC) assay that utilizes four breast cancer protein biomarkers (ER, PR, HER2, and Ki-67) to assess risk in patients with ER+ ESBC. 24 Initial analysis was performed in a single laboratory using unique antibodies for IHC, careful IHC4 was also evaluated in a convenience sample of 786 ER+, post-menopausal, and pre-menopausal ESBC patients from Nottingham who were either untreated or treated with ETx alone. 24 Due to manual reading and the use of a different antibody, Ki-67 levels were nearly 2.5 times higher than in the ATAC cohort, requiring rescaling.
After adjustment, the modified IHC4 score was prognostic for outcome when added to the clinical score (HR, 3.9; P < 0.0001).
Sgroi et al evaluated IHC4 in Cuzick's LN− ATAC population, the same population in which IHC4 was developed, to confirm the prognostic value of the immunohistochemical assay. 8, 24 In the 915 patients, the authors examined the likelihood ratio for both IHC4 and BCI; IHC4 appeared prognostic for recurrence to 5 years in multivariable analysis. Stephen and colleagues also showed that IHC4 was prognostic to 5 years using independent Cox analysis in samples from the Edinburgh BCI series and TEAM trial. 25 Commercialization of the assay by Genoptix, may address some of these issues, but validation data for the commercial assay is currently unavailable.
| MammaPrint
MammaPrint is a microarray-based assay that uses the expression levels of 70 selected genes to classify tumors as "poor signature" or MammaPrint was also assessed in LN+ subjects from a multiinstitution convenience sample that identified significant association between the gene signature and BCSS (log rank P < 0.001) or 10-year DMFS (log rank P = 0.001). 32 In another convenience sample, Wittner demonstrated a negative predictive value of 100% in 100 LN− postmenopausal patients from the Massachusetts General
Hospital. However, the corresponding positive predictive value was only 12%. Furthermore, there was no significant difference in TTDR between the gene signature groups. 33 Mook, used a sample of postmenopausal LN− patients from the NKI to show significant association between the gene signature and BCSS (log rank P = 0.036), but not DMFS (log rank P = 0.07). 34 MammaPrint is one of only two assays for which there is published Level I-A evidence supporting prognosis. 35 The 
| Prosigna
The Prosigna breast cancer test is a multiplex assay that measures the expression of 50 classification genes and eight housekeeping genes in order to assign a "risk of recurrence" (ROR) score to patients with ESBC.
The assay, initially termed PAM50, was adapted and commercialized by Nanostring, Inc. for use in their nCounter analytic system, consisting of a single hybridization reaction with specific labeled probes. 50 Gene expression of 46 of the genes is used to compare a specimen to prototypical intrinsic biologic subsets originally described by Perou. status. 54 The ROR score provided a significant additional increase in prognostic information over the CLP (log −likelihood test: When assessing a genomic test, an appreciation of the analytic validity, clinical validity, and clinical utility are paramount. Peer-reviewed published evidence, rather than podium presentations or a marketing clearance, should be the prime consideration. Studies should be logical and easily interpreted, with unequivocal primary and secondary endpoints. Any assessment of chemotherapy benefit prediction should be conducted in a randomized clinical trial that compared patients treated with chemotherapy to patients who did not receive chemotherapy.
Although differences in neoadjuvant pCR may suggest assay value, differences in the rate of pCR do not directly correlate with long-term outcome, particularly when assessing heterogeneous populations. 59, 60 Clinical endpoint data should capture short-term and relevant long-term cancer events.
Analytic validation reflects the standardized performance and reproducibility of a specific assay technique. Ideally, an assay's methodology should be fixed prior to conducting definitive clinical validation studies so that the validation evidence adequately reflects performance of the commercial test. Dissonance between a validation test and the commercially marketed assay is illustrated by the BCI, which has undergone several iterations. The first two key BCI studies used opposite arms of the same Stockholm trial for development and validation. 14, 16 An example of confounding population heterogeneity is evident in the original MammaPrint validation study that included an assortment of different patient populations receiving an assortment of varying treatments. 30 Of the 295 patients in the study, 144 were node positive and 151 were node negative. ER+ was a characteristic in 69, with 226 ER−. Nearly 37% happened to receive adjuvant CTx, while 56% had been untreated. No patient treatments were randomized or protocoldirected. In the subsequent study of Buyse, none of the patients received any systemic adjuvant treatment. 31 In the BCI validation study, using the MA.14 clinical trial, 35% of patients received adjuvant CTx, confounding the prognostic value of the assay. As a result, the impact of CTx on the prognostic value of BCI remains uncertain. 18 .
The TMUGS process for assessing genomic assays, is designed to standardize validation by assigning levels of evidence to all supporting published studies. 6, 7 The best support for any gene expression assay comes from a prospectively designed and prospectively conducted More recently, the OPTIMA Prelim Trial evaluated five assays, including four of the tests discussed in this review (Oncotype DX, MammaPrint, Prosigna, and NexCourse Breast-IHC4). Each assay was performed in its manufacturer's own commercial laboratory. 72 Remarkably, there was significant disagreement between assays, with the overall level of agreement only "moderate" (κ = 0.40-0.59).
The authors were perplexed that multiple assays, each with independent validation for prognosis, could have such disagreement.
They suggested that assay concordance was no better than classic pathologic grading. However, OPTIMA Prelim did not measure longterm patient outcomes and could not provide independent validation of each of the competing assays, nor could it identify the most accurate of the disparate tests. The poor concordance between all tests suggests that one well validated assay cannot reliably be replaced with others with less robust validation.
The challenge of medical decision-making is to provide the best care for today's patients while continually assessing new diagnostic and treatment paradigms for those in the future. Adjuvant therapy provides an opportunity to reduce the chance of DR and death, but carries its own risk of short and long-term toxicity. Modern therapies also generate significant costs to individuals and healthcare systems.
Genomic classifiers that provide accurate prognostic information and reliable benefit prediction personalize the selection of treatment. They improve the likelihood of favorable long-term outcome while conserving healthcare resources. However, the choice should be made on the basis of a rigorous analysis of the ever-changing supporting data. 
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